PT-141 vs Melanotan II — melanocortin receptor selectivity compared

PT-141 and Melanotan II are constantly named in the same breath, and the assumption is that they are two versions of one idea. They are closer than that — one is literally derived from the other — and yet they are not interchangeable. Both are cyclic melanocortin agonists built on the same ancestral pharmacophore; the difference that matters is which receptor subtypes each one switches on. This is a research-first comparison of the PT-141 parent synopsis’s central contrast: same family, same active motif, different receptor selectivity — and that selectivity is the whole comparison.

Same family, same pharmacophore — different selectivity

Start with what the two share, because it is most of the molecule. Both PT-141 and Melanotan II descend from α-melanocyte-stimulating hormone (α-MSH), the natural melanocortin ligand, and both are cyclic peptides that retain its His-Phe-Arg-Trp (HFRW) tetrapeptide — the conserved core that every melanocortin agonist uses to dock into the receptor binding pocket. So at the level of “what kind of molecule is this,” the honest answer is that they are members of the same small structural family, not unrelated compounds.

What separates them is not the active motif but the profile of receptors that motif ends up activating. There are five melanocortin receptor subtypes (MC1R through MC5R), and a melanocortin agonist is defined less by the fact that it binds the family than by which subtypesit favours and how strongly. That single axis — receptor-subtype selectivity — is where PT-141 and Melanotan II diverge, and it is the entire content of the comparison below.

The structural relationship

PT-141 is the research designation for bremelanotide, a cyclic heptapeptide of roughly 1,025 Da. It was not designed from scratch: it is derived from Melanotan II by removing the C-terminal amide group and substituting a residue, which leaves the HFRW core intact while altering the molecule’s shape at the periphery. That small set of changes is enough to shift the receptor-binding profile — the derivative reads the receptor family differently from its parent compound.

Melanotan II, in turn, is itself a synthetic cyclic analogue of α-MSH. So the lineage runs α-MSH → Melanotan II → PT-141, each step a deliberate structural edit of the one before. This matters for the comparison because it explains why the two compounds are so often conflated: they are genuinely close relatives. It also explains why “are they the same?” has a precise answer — no, but one is the direct structural descendant of the other.

The cleanest way to hold the relationship: Melanotan II is the broad-spectrum parent; PT-141 is the narrowed-down derivative. Same pharmacophore, edited periphery, different receptor emphasis.

Receptor selectivity — the core contrast

Here is the difference that does all the work. Melanotan II is a broad melanocortin agonist: it activates MC1R, MC3R, MC4R and MC5R, without a strong preference among them. PT-141, by contrast, carries substantially higher selectivity for MC3R and MC4R and much weaker activity at MC1R. The receptor-pharmacology literature that consolidates melanocortin-agonist selectivity profiles documents exactly this kind of subtype-preference gradient across the receptor family [1].

Put plainly: the parent compound presses every button on the melanocortin panel; the derivative presses MC4R (and MC3R) hard and barely touches MC1R. Neither is “stronger” in the abstract — they aim at different receptor subsets. Everything practically observable about how the two compounds behave follows from this selectivity gap, starting with the most visible one.

The pigmentation difference

MC1R is the pigmentation receptor — the melanocortin subtype expressed on melanocytes that, when activated, drives the production of melanin in skin. This is the single receptor that most cleanly separates the two compounds in observable terms. Because Melanotan II is a strong MC1R agonist, it produces a marked skin-pigmentation effect; in research framing it is the melanocortin compound most associated with the tanning-research phenotype.

PT-141 does not. Its activity at MC1R is weak, so at comparable doses it does not produce the pigmentation phenotype that defines Melanotan II. This is the most practically visible difference between the two and the one a researcher would notice first: the broad-spectrum parent tans, the MC4R-selective derivative does not. The contrast is a direct readout of the selectivity table above — same family, but only one of them lights up the pigmentation receptor.

Central versus peripheral receptor profile

Where Melanotan II’s broad MC1R activity points outward to the skin, PT-141’s MC4R bias points inward to the central nervous system. MC4R is densely expressed in the hypothalamus, and the bremelanotide-specific mechanism work locates its action on MC4R-bearing neurons in the medial preoptic area (mPOA), with downstream dopaminergic signalling — a central, hypothalamic profile rather than a peripheral one [2]. That central direction is exactly what you would predict from a compound that favours MC4R and avoids MC1R.

The receptor engagement is not confined to neurons, though, and that breadth is itself a research finding. Drug-repositioning work in non-CNS systems has mapped bremelanotide’s engagement of MC3R/MC4R in glioblastoma cell lines — a receptor-mechanism and repositioning study examining how the molecule interacts with melanocortin receptors expressed on those cultured cells, not a treatment claim of any kind [3]. The useful takeaway is narrow and mechanistic: the same MC3R/MC4R selectivity that defines PT-141 centrally is also detectable in cell-line models, which is why the molecule keeps surfacing as a receptor-pharmacology tool.

Melanotan II broadcasts across the receptor family and reads out at the skin; PT-141 narrows onto MC3R/MC4R and reads out centrally. One axis — selectivity — explains both the tan and the hypothalamus.

What they share, and a regulatory note

For all their selectivity differences, the two compounds share a category: both are supplied as research-grade lyophilised material for non-clinical investigation in this market, and both rest the bulk of their human story on early-stage or non-clinical evidence. The regulatory status, however, is where they part decisively. PT-141’s molecule, bremelanotide, is additionally the active ingredient in an FDA-approved prescription product — approved in 2019 for a specific clinical indication. Melanotan II is not approved anywhere, by any regulator, for any indication.

That asymmetry is worth stating precisely. The approved medicine containing bremelanotide is a separate registered product with its own manufacturer and quality-control regime; the research-grade peptide we discuss here is not that product and carries no claim of clinical equivalence to it. Melanotan II has no such approved counterpart at all. So even though the two molecules are structural relatives, their regulatory positions could hardly be more different — one has a single approved indication on record, the other has none.

An honest verdict

Framed as “which,” the comparison mostly dissolves: PT-141 and Melanotan II are not rival tools for one job — they are a parent compound and its narrowed-down derivative, separated almost entirely by receptor-subtype selectivity. Melanotan II is the broad melanocortin agonist whose MC1R activity makes it the pigmentation compound; PT-141 is the MC3R/MC4R-selective descendant whose weak MC1R activity removes that phenotype and whose MC4R bias points it at central signalling. Same HFRW pharmacophore, one structural edit, two different receptor profiles.

The limits are equally honest. The selectivity contrast and the central-versus-peripheral picture rest on receptor pharmacology and mechanism studies, including cell-line work; they are not licences to infer downstream human outcomes for either compound. PT-141’s molecule has a single approved indication on the regulatory record; Melanotan II has none. Both remain research-grade here, supplied for non-clinical investigation. Whatever a label or forum implies, the published evidence on this pair is about receptor selectivity and mechanism — nothing beyond that has been established for the research-grade materials.

Related in the PT-141 cluster

• Parent synopsis: PT-141 (bremelanotide) — the melanocortin-pathway peptide.
• Mechanism deep-dive: PT-141 mechanism research.
• Dosing-research context: PT-141 dosing-research protocols.
• Category overview: research peptides in the UAE.
• Research-consultation page: PT-141 10 mg.

Further reading

Peer-reviewed citations used inline:

• [1] Shadiack et al. — Curr Top Med Chem 2007. Melanocortin receptor pharmacology — subtype selectivity profiles across the MC1R–MC5R family.
• [2] Pfaus et al. — CNS Spectr 2021. The neurobiology of bremelanotide — hypothalamic MC4R activation in the mPOA and downstream dopaminergic signalling.
• [3] Suzuki et al. — Anticancer Res 2024. Bremelanotide engages MC3R/MC4R in glioblastoma cell lines — a receptor-mechanism / drug-repositioning study (not a treatment claim).

Last reviewed 12 June 2026. Wellness Labs supplies PT-141 as research-grade lyophilised powder for non-clinical investigation. This article is research education and not medical advice; it is not a substitute for the FDA-approved prescription medicine that contains the same active ingredient. Editorial inbox: info@uaewellnesslab.com.